Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel) in Chemotherapy-naive Castration-Resistant Prostate Cancer Patients.

Trial Profile

Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel) in Chemotherapy-naive Castration-Resistant Prostate Cancer Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 May 2013 Planned end date changed from 1 Jun 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top